Efficacy and safety of the long-acting fusion inhibitor albuvirtide in antiretroviral-experienced adults with human immunodeficiency virus-1: interim analysis of the randomized, controlled, phase 3, non-inferiority TALENT study

BACKGROUND: Albuvirtide is a once-weekly injectable human immunodeficiency virus (HIV)-1 fusion inhibitor. We present interim data for a phase 3 trial assessing the safety and efficacy of albuvirtide plus lopinavir-ritonavir in HIV-1-infected adults already treated with antiretroviral drugs. METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales: Su, Bin, Yao, Cheng, Zhao, Qing-Xia, Cai, Wei-Ping, Wang, Min, Lu, Hong-Zhou, Chen, Yuan-Yuan, Liu, Li, Wang, Hui, He, Yun, Zheng, Yu-Huang, Li, Ling-Hua, Chen, Jin-Feng, Yu, Jian-Hua, Zhu, Biao, Zhao, Min, Sun, Yong-Tao, Lun, Wen-Hui, Xia, Wei, Sun, Li-Jun, Dai, Li-Li, Jiang, Tai-Yi, Wang, Mei-Xia, Zheng, Qing-Shan, Peng, Hai-Yan, Wang, Yao, Lu, Rong-Jian, Hu, Jian-Hua, Xing, Hui, Shao, Yi-Ming, Xie, Dong, Zhang, Tong, Zhang, Fu-Jie, Wu, Hao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7752691/
https://www.ncbi.nlm.nih.gov/pubmed/33252379
http://dx.doi.org/10.1097/CM9.0000000000001273

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7752691/
https://www.ncbi.nlm.nih.gov/pubmed/33252379
http://dx.doi.org/10.1097/CM9.0000000000001273

Ejemplares similares